A Phase 2 interventional study of Glucagon-like peptide 1 receptor agonist in Endometrioid Endometrial Adenocarcinoma, sponsored by University of Florida. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by University of Florida · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.
Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 483rd largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2026, is one of 178 in phase 2, reaches primary completion later than 218 of the 283 other live ones, and was the 647th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, China and 2 more countries
Ages 18+ · Women only
University of Oklahoma · Sites in United States
Ages 18+ · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Sutro Biopharma, Inc. · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 277 · Phase 2 264 · Phase 3 40 · Phase 4 3
First in 1987; this study’s year is marked. 46 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 60 across the 591 interventional studies, 148 across the 100 observational. Of the 386 that completed or were terminated, 132 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 715 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
95 of the studies in Endometrial Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03785288Phase 3Kara Romano, MDVaginal Cuff Brachytherapy Fractionation Study | 2027-01-30 |
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT05256225Phase 3National Cancer Institute (NCI)Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | 2027-10-31 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
Add all 95 to your calendar (.ics) → With an account.
Among the 715 studies in Endometrial Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1. These medications trigger the pancreas to release insulin which can help lower blood sugar levels and delay gastric emptying. The recent FDA approval of GLP-1RAs has changed the landscape for pharmacotherapy for weight loss. These hormone-based obesity medications are novel and revolutionary in obesity medicine. Liraglutine, semaglutide, and tirzepatide have become exceedingly popular for their effects on weight loss and obesity-related comorbidities. More recently, GLP-1RAs have exhibited risk reduction of various obesity associated cancers, including endometrial cancer but their exact role in prevention and treatment has yet to be measured.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥ 30 kg/m2 and one of the following (per medical record or self-report):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Glucagon-like peptide 1 receptor agonist
Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for as clinically indicated by the treating physician or until the subject receives clearance for staging hysterectomy or for pregnancy pursuit. The choice of glucagon-like peptide 1 receptor agonist for each subject will be at the treating physician's discretion. Subjects will discontinue the glucagon-like peptide 1 receptor agonist 2 weeks before any elective surgical procedure.
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., OrforglipronStudies of OrforglipronOrforglipron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Time from start of GLP-1RA to clearance of staging hysterectomy
Determine the time from start of GLP-1RA treatment to clearance for staging hysterectomy in patients with poor surgical candidacy for a hysterectomy.
Time frame: 12 months
Time from start of GLP-1RA to clearance for pregnancy pursuit
Determine the time from start of GLP-1RA treatment to clearance for pregnancy pursuit in patients pursuing fertility sparing.
Time frame: 12 months
Endometrial pathologic response
Determine the endometrial pathologic response 6 months after beginning GLP-1RA treatment
Time frame: 6 months after beginning GLP-1RA treatment
Endometrial pathologic response
Determine the endometrial pathologic response 12 months after beginning GLP-1RA treatment
Time frame: 12 months after beginning GLP-1RA treatment
Length of surgery
Determine the length of staging hysterectomy surgery
Time frame: Intraoperative
Number of nights in hospital
Determine the number of nights spent in the hospital for staging hysterectomy
Time frame: 12 months
Postoperative complications
Determine the postoperative complications following staging hysterectomy
Time frame: 12 months
Patient-reported quality of life
Compare patient-reported quality of life, as measured by the EORTC QLQ-C30, v3.0 between baseline and at 6 months after beginning GLP-1RA treatment
Time frame: 6 months
Patient-reported quality of life
Compare patient-reported quality of life, as measured by the EORTC QLQ-C30, v3.0 between baseline and at 12 months after beginning GLP-1RA treatment
Time frame: 12 months
Patient-reported quality of life
Compare patient-reported quality of life, as measured by the EORTC QLQ-C30, v3.0 between baseline and at end of GLP-1RA treatment
Time frame: at either clearance for pregnancy pursuit or staging hysterectomy, which will ideally occur by 12 months after beginning study treatment
Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 31 months after the start.
Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 31 months is below that.
Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Semaglutide · Tirzepatide · Orforglipron